Ann: Quarterly Activity Report & Appendix 4C, page-38

First 38 Last

Share
Profile

Follow
flotsam222

4,936 Posts.

336

07/05/24

09:33

Post #: 73697677
Share

Originally posted by Pledge: ↑

What are the details on the options? I'll look it up if you're not inclined to provide.

I can't see how they are factoring in the R&D refund but I'll give it a rough go? That is expected to come in, in the Dec 2024 QAR.

This is a worry for mine:

This is from the Dec 2023 Quarterly as above.

The spend went from A$883K a quarter to A$2.2M per quarter and I suspect this will increase dramatically with this:

A$9M in cash. Let's say this current quarter and the next costs the same as the last (A$2.2M). That leaves A$5.6M and let's hypothesize that Q4 of this calendar year is say A$3.2M (I am being conservative, I think it will be more) to finish all candidate enrolment for GVHD. That leaves A$2.4M.

Let's assume the tax rebate is A$3M. That takes us back up to $5.4M going into 2025.

On A$2.2M a quarter (GVHD will continue to cost! and I think it will increase beyond this), that leaves less than 3 quarters and 'conks out' in 1st quarter 2025/26 financial year (or before if the costs continue to increase beyond these estimates).

It's cutting it fine, withstanding the options, as you nominated. But it fits, I suppose. Their statements holds water, just - but that's all it has to do.

Partnership and/or CR by the end of this year. This or next quarter, I reckon.

Something has to happen to continue.

Expand

It shouldn't be too difficult and likely at a substantially higher price if they go the CR route, especially if MSB gains approval.

I'm betting on a partnership though.

The market also knows that when both companies are selling products CYP will likely outcompete MSB both on price and treatment acceptance by patients so there should be plenty of interest here should MSB get the nod.

Heres hoping.

CYP Price at posting: 23.5¢ Sentiment: None Disclosure: Held
11 Upvote

0 Great analysis

Reply

Top Stories

GTR

GTI extends uranium mineralisation at Lo Hema through development drilling

CHN

Chalice jumps on Putin nickel export ban threat – but then there's bad news

3 stocks with antimony news on Thursday

DXB

Dimerix begins recruiting young kidney disease patients in Mexico for Phase 3

CU6

Clarity progresses SECuRE trial with positive safety results